MA53118A - Alcoxy pyrazoles en tant qu'activateurs de la guanylate cyclase soluble - Google Patents
Alcoxy pyrazoles en tant qu'activateurs de la guanylate cyclase solubleInfo
- Publication number
- MA53118A MA53118A MA053118A MA53118A MA53118A MA 53118 A MA53118 A MA 53118A MA 053118 A MA053118 A MA 053118A MA 53118 A MA53118 A MA 53118A MA 53118 A MA53118 A MA 53118A
- Authority
- MA
- Morocco
- Prior art keywords
- alcoxy
- pyrazoles
- guanylate cyclase
- soluble guanylate
- cyclase activators
- Prior art date
Links
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 title 1
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 title 1
- 239000003119 guanylate cyclase activator Substances 0.000 title 1
- 150000003217 pyrazoles Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862696887P | 2018-07-12 | 2018-07-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53118A true MA53118A (fr) | 2021-05-19 |
Family
ID=67314737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053118A MA53118A (fr) | 2018-07-12 | 2019-07-09 | Alcoxy pyrazoles en tant qu'activateurs de la guanylate cyclase soluble |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11690848B2 (https=) |
| EP (1) | EP3820470B1 (https=) |
| JP (2) | JP2021530488A (https=) |
| KR (1) | KR20210032443A (https=) |
| CN (1) | CN112384214A (https=) |
| AU (1) | AU2019301887A1 (https=) |
| BR (1) | BR112020025670A2 (https=) |
| CA (1) | CA3103727A1 (https=) |
| CL (1) | CL2021000023A1 (https=) |
| EA (1) | EA202190193A1 (https=) |
| MA (1) | MA53118A (https=) |
| MX (1) | MX2021000405A (https=) |
| PH (1) | PH12021550075A1 (https=) |
| WO (1) | WO2020011804A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118900690A (zh) * | 2022-03-21 | 2024-11-05 | 勃林格殷格翰国际有限公司 | 用于治疗门脉高压的可溶性鸟苷酸环化酶活化剂 |
| WO2024097316A1 (en) | 2022-11-04 | 2024-05-10 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators for treating systemic sclerosis |
| US20240199590A1 (en) | 2022-12-09 | 2024-06-20 | Boehringer Ingelheim International Gmbh | Solid forms of a sgc activator |
| WO2025036839A1 (en) * | 2023-08-16 | 2025-02-20 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators for treating clinically significant portal hypertension and decompensated cirrhosis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2748798T3 (es) | 2012-09-07 | 2020-03-18 | Boehringer Ingelheim Int | Alcoxi pirazoles como activadores de la guanilato ciclasa soluble |
| BR112018015718A2 (pt) * | 2016-02-01 | 2019-01-08 | Ironwood Pharmaceuticals Inc | utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash) |
| US10925876B2 (en) | 2016-05-18 | 2021-02-23 | Merck Sharp & Dohme Corp. | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders |
-
2019
- 2019-07-09 EP EP19740509.5A patent/EP3820470B1/en active Active
- 2019-07-09 EA EA202190193A patent/EA202190193A1/ru unknown
- 2019-07-09 KR KR1020217004281A patent/KR20210032443A/ko not_active Ceased
- 2019-07-09 CN CN201980045881.XA patent/CN112384214A/zh active Pending
- 2019-07-09 MX MX2021000405A patent/MX2021000405A/es unknown
- 2019-07-09 WO PCT/EP2019/068448 patent/WO2020011804A1/en not_active Ceased
- 2019-07-09 CA CA3103727A patent/CA3103727A1/en active Pending
- 2019-07-09 US US17/258,759 patent/US11690848B2/en active Active
- 2019-07-09 JP JP2021500613A patent/JP2021530488A/ja active Pending
- 2019-07-09 AU AU2019301887A patent/AU2019301887A1/en not_active Abandoned
- 2019-07-09 MA MA053118A patent/MA53118A/fr unknown
- 2019-07-09 BR BR112020025670-6A patent/BR112020025670A2/pt not_active IP Right Cessation
-
2021
- 2021-01-06 CL CL2021000023A patent/CL2021000023A1/es unknown
- 2021-01-12 PH PH12021550075A patent/PH12021550075A1/en unknown
-
2024
- 2024-03-27 JP JP2024052193A patent/JP2024095711A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021000405A (es) | 2021-03-25 |
| CA3103727A1 (en) | 2020-01-16 |
| KR20210032443A (ko) | 2021-03-24 |
| WO2020011804A1 (en) | 2020-01-16 |
| EA202190193A1 (ru) | 2021-06-16 |
| AU2019301887A1 (en) | 2021-01-07 |
| JP2021530488A (ja) | 2021-11-11 |
| JP2024095711A (ja) | 2024-07-10 |
| US20210121473A1 (en) | 2021-04-29 |
| US11690848B2 (en) | 2023-07-04 |
| BR112020025670A2 (pt) | 2021-03-16 |
| CL2021000023A1 (es) | 2021-06-11 |
| CN112384214A (zh) | 2021-02-19 |
| PH12021550075A1 (en) | 2021-09-20 |
| EP3820470A1 (en) | 2021-05-19 |
| EP3820470B1 (en) | 2024-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3883570A4 (en) | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | |
| EP3621624A4 (en) | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | |
| MA47460A (fr) | Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase | |
| EP3853220A4 (en) | QUINOXALINE DERIVATIVES AS ANTI-TUMORS AGENTS | |
| MA53150A (fr) | Composés de benzimidazole en tant qu'inhibiteurs de c-kit | |
| MA47123A (fr) | Dérivés de benzooxazole en tant qu'mmunomodulateurs | |
| MA53377A (fr) | Composés de pyridin-2-one utiles en tant qu'antagonistes de smarca2 | |
| MA47125A (fr) | Dérivés de pyrazole en tant qu'inhibiteurs de malt1 | |
| EP3953331A4 (en) | PYRAZOLESULFONAMIDES AS ANTITUMORS | |
| MA52754A (fr) | Composés hétérocycliques tricycliques en tant qu'activateurs de sting | |
| EP3755311A4 (en) | INDANAMINE AS PD-L1 ANTAGONISTS | |
| MA53118A (fr) | Alcoxy pyrazoles en tant qu'activateurs de la guanylate cyclase soluble | |
| EP3344644A4 (en) | CYCLIC DI NUCLEOTIDE COMPOUNDS AS STING AGONISTS | |
| MA52486A (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
| EP4013496A4 (en) | THROMBOSOMES AS AN AGENT FOR REMOVING THE THROMBOCYTE AGGREGATION-INHIBITING EFFECT | |
| FR25C1047I1 (fr) | Aminopyrazoles en tant qu'inhibiteurs sélectifs de janus kinase | |
| MA46745A (fr) | Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v | |
| MA45153A (fr) | Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux | |
| EP3656769A4 (en) | ARYL-PHOSPHORUS-OXYGEN COMPOUND AS EGFR KINASE INHIBITOR | |
| EP3861343A4 (en) | ULTRA-BRIGHT FLUORESCENT NANOSTRUCTURES AS UNIVERSAL AMPLIFIERS | |
| MA54939A (fr) | Hydroxypyridoxazépines utilisées en tant qu'activateurs de nrf2 | |
| MA46878A (fr) | Composés de benzodiazolium en tant qu'inhibiteurs d'enac | |
| EP3733671A4 (en) | AMINOFLUOROPERIDINE DERIVATIVES AS KINAS INHIBITOR | |
| EP3733673A4 (en) | OXY-FLUORPIPERIDE DERIVATIVES AS KINAS INHIBITOR | |
| MA46824A (fr) | Composés de triazole substitués par alkyle en tant qu'agonistes du récepteur apj |